Is EORTC up or down today?
EORTC is down 0.77% today, last at 163.78. This stock moved -0.77% versus the prior close.
EORTC · EORTC
EORTC (EORTC) is trading at 163.78, down 0.77% on the session. EORTC sits at the 50% mark of its 52-week range.
Leading the coverage: “Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026 - Yahoo Finance” (Google News Company, 27d ago). EORTC is -8.53% since story.
EORTC trades on a trailing P/E of 41.4.
Analyst firms are mostly reiterating — no strong directional shift lately.
EORTC is down 0.77% today, last at 163.78. This stock moved -0.77% versus the prior close.
Leading the coverage: “Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026 - Yahoo Finance” (Google News Company, 27d ago). EORTC is -8.53% since story. Dominant story: Institutional buyers pile into EORTC, filings show (1 source, bullish) RSI unavailable Price sits at 50% of its 52-week range Social sentiment loads separately — see the Social tab.
Analyst firms are mostly reiterating — no strong directional shift lately.
Historical price chart unavailable
Live quote in the header is real, but OHLC history could not be loaded from Yahoo Finance or fallback providers. Charts use Yahoo when configured correctly — check server logs for provider errors.
Institutional buyers pile into EORTC, filings show
EORTC slips after cautious guidance rattles investors
EORTC volatility spikes as options activity jumps
Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026 - Yahoo Finance
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the 38th EORTC-NCI-AACR Symposium 2026 - Yahoo Finance